Relief is Still an Incredible Play $RLFTF

The drama between Relief Therapuetics and their supposed American partner NRx continues, which is about greed, timing and a Covid-19 treatment in a world of endemic Delta. As both stocks plummet, and a bear market for penny and OTC stocks continue, $RLFTF could be picked up at quite a bargain if you understand where the bottom of the bear market for penny stocks this small will end.

Relief is a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported this week, that it has received scientific advice from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) relating to its lead investigational drug, RLF-100 TM (aviptadil), for the treatment of respiratory deficiency due to severe COVID-19.

Suffice to say I’m not a huge for of JR Javitt these days. Relief also reported that, to date, NeuroRx has not provided it with all of the data from its U.S. Phase 2b/3 study evaluating intravenously administered aviptadil for the treatment of respiratory failure in critically ill patients with COVID-19. There can be no assurance that NeuroRx will provide the required information.

So Relief is taking its great product and patent to the European area which you sort of wish it had sped up a long time ago.

Relief also reported today that it has held discussions with the European Medicines Agency (EMA) pertaining to the regulatory path forward for RLF-100 in the European Union. Relief has informed EMA that it will proceed with further dialogue with the MHRA once it has compiled critical information related to the study conduct, clinical data and the drug product.

As a stock $RLFTF is OTC and could go down as low as $0.10 if I’m not mistaken, though is likely worth close to $2.00 if this is as good as our due diligence thinks it is. Obscure Swiss Pharma company, but good product diversification and patents. Not really sure why Michael Miller writes such long winded sentences, it’s 2021 guys.

The guidance, which was provided in the context of a recent meeting that Relief held with the MHRA, included advice on the appropriate pathway for submission of an application for conditional marketing approval (CMA) [1] for the intravenous formulation of RLF-100.

It is subject to provision of all data from the U.S. Phase 2b/3 study conducted by Relief’s collaboration partner, NeuroRx, Inc. (“NeuroRx”) According to the MHRA, a CMA through rolling review or expedited review process would be an appropriate pathway to ensure speedy access to beneficial treatments for patients infected with COVID-19.

So given the penny stock bear market and the legal delays and stalling by NRx, we might have to wait until 2022 to really see the potential of this drug saving lives just as critical ICU Nursing shortages will really be impacting health systems. In some states, provinces and countries we’re already seeing that with the 4th wave.

Relief is one of my favorite European stocks to be honest. Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief’s lead drug candidate, RLF-100 TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19.

As part of its pipeline diversification strategy. I think I’ve written about this stock over ten times by now, and Relief has the majority of the revenue streams in the future, as compared to NRx, it’s supposedly competent and much larger U.S. partner.

How is this stock even under $0.20? It makes no sense, but the bear market for micro cap stocks knows no bottom, thus far that we know of. It’s impossible to invent in OTC and penny stocks under $2 in such an environment. Relief’s recently completed acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH bring a diverse pipeline of marketed and development-stage programs. So this company is simply more mature than its current market cap would indicate.

In an era of declining vaccine efficacy, and potential more virulent forms of Delta, Relief’s product could be the last resort in live or die triage scenarios at ICUs where nurses are working at around 150% capacity. Just look at the province of Alberta in Canada, and you realize how grim it’s going to get. Scientists now recognize that herd immunity essentially does not exist for Delta and those unvaccinated are around 12x more likely to die from it.

It’s hard to understand why JR is withholding the data, either they want a bigger cut or it’s just not that great. In a world where lives mattered more than pharma greed, the drug would already have gotten an EUA as a treatment. But Pharma is notoriously corrupt, price fixing for drugs that many people cannot even afford. Withholding data only harms the revenue of both companies and delays whether it will even be impactful once it finally gets approved depending on Delta’s situation globally.

Relief is just $0.157 cents at the time of writing while $NRXP is $10.50, one is under-valued and one is over-valued, can you tell which is which? You have to hold out in the OTC market and penny stock bear market likely for November or if a major crash arrives and the Vix spikes. The bear market has lasted 7 months already, it could last a long longer realistically. Buying a penny stock during a bear market for OTC stock is essentially like gambling unless you are very patient and average down.

In the meantime, I will try not to take it personally Javitt. Handsome devil, maybe a bit greedy, gives a good Bloomberg or CNBC interview. Mumbles a bit. Pictured above.

Similar Posts